Lv3
240 积分 2024-02-18 加入
Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
4个月前
已完结
MA04.02 Nautika1: Clinical Outcomes and Pathologic Regression With Neoadjuvant Alectinib in Resectable Stage IB-IIIB ALK + NSCLC
5个月前
已关闭
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial
5个月前
已完结
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing
7个月前
已完结
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
9个月前
已完结
皖公网安备34019202002308
